The NIHR Cardiovascular Healthcare Technology Co-operative (HTC) has been set up to identify, encourage and facilitate the development of new medical devices and technology driven solutions that will improve the diagnosis, treatment and well-being of patients with cardiovascular disease.

Cardiovascular disease is an umbrella term used to describe a set of different diseases affecting the heart or the surrounding blood vessels, it is sometimes called heart and circulatory disease. The World Health Organisation (WHO) regularly releases statistics on diseases and their impact. The information dedicated to cardiovascular disease shows the huge impact of this disease.

Cardiovascular disease is the number one cause of death with more people dying annually as a result of the disease than any other cause. In 2008, cardiovascular disease was estimated to be the cause of 30 percent of all global deaths. In addition, sufferers of heart disease have a reduced quality of life and require expensive treatments and diagnostics, these in turn increase costs for the NHS. The figures from WHO show that there is great potential and need to improve the diagnosis and treatment of cardiovascular disease.

The NIHR Cardiovascular HTC works with researchers, clinicians, companies and patients to develop and de-risk new medical technologies and access funding streams. The HTC forms collaborations and funds small projects to support technologies at the proof of concept stage, where we might have a prototype in the lab, all the way to productionisation where there is a product that can be bought. For more information see the Our Purpose page in the About Us section and review our 2016 HTC brochure.

The Cardiovascular HTC has been established and supported through King’s College London and Guy’s and St Thomas’ NHS Trust.

KCL_box_red pin 485rgb GuysAndStThomasLogo

Latest News